BGB-11417 (BCL): A phase 1 trial of BGB-11417 in people with B cell malignancies
This trial is testing BGB-11417 alone, or with zanubrutinib or obinutuzumab, in the treatment of B cell lymphomas.
You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT04277637
Trial aim and background
The aim of this trial is to find out how safe and well tolerated the medication BGB-11417 is in people with B cell lymphomas as well as determining the maximum tolerated dose and recommended dose. The aim is also to see how effective it is when given alone or when in combination with zanubrutinib or obinutuzumab.
It will be aimed at people with refractory or relapsed B cell lymphomas who have failed to respond to at least one standard treatment.
This is a phase 1 (early phase) trial. Little is known about the safety and effectiveness of this treatment. You might not benefit from the treatment, but the trial will give important information about this new treatment, which could help other people in the future.
Who can enter
Adults with marginal zone lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, transformed B-cell lymphoma, waldenstrom's macroglobulinemia or chronic lymphocytic lymphoma which has failed to respond to, or has relapsed after one systemic treatment may be eligible for this trial.
Locations
Recruitment is taking place at the Oxford University Hospitals NHS Trust, Oxford
Further information
More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/ct2/show/NCT04277637
Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.